TARRYTOWN, N.Y., Feb. 4, 2020 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an
expanded agreement with the U.S. Department of Health and Human
Services (HHS) to develop new treatments combating the novel
coronavirus, 2019-nCoV, which was recently declared a global public
health emergency by the World Health Organization. Regeneron has a
number of active collaborations with HHS's Biomedical Advanced
Research and Development Authority (BARDA), part of the Office of
the Assistant Secretary for Preparedness and Response (ASPR),
including a collaboration to advance Regeneron's investigational
Ebola treatment REGN-EB3, which demonstrated positive clinical data
in 2019.
The HHS and Regeneron Other Transaction Agreement (OTA),
originally established in 2017, is focused on discovery, research,
development and manufacturing of a portfolio of antibodies
targeting up to 10 pathogens that pose significant risk to public
health, now including the Influenza virus and 2019-nCoV. This
effort utilizes Regeneron's proprietary
VelociSuite® technologies – including the
VelocImmune® platform which uses a unique
genetically-engineered mouse with a humanized immune system that
can be challenged with all or parts of a virus of interest – to
facilitate swift identification, preclinical validation and
development of promising antibody candidates. Regeneron's rapid
response VelociSuite® technologies are
particularly well-suited for use in quickly-developing outbreak
situations, as was done for Ebola.
"The life-saving results seen with our investigational Ebola
therapy last year underscore the potential impact of Regeneron's
rapid response platform for addressing emerging outbreaks," said
George D. Yancopoulos, M.D., Ph.D.,
President and Chief Scientific Officer of Regeneron. "Our unique
suite of technologies expedites and improves the drug discovery and
development process at every stage, positioning Regeneron to
respond quickly and effectively to new pathogens. We are eager to
expand our productive collaboration with BARDA and are already
working hard to address the novel coronavirus that is causing
worldwide concern."
The Other Transaction Authority provides a funding and
collaboration vehicle for HHS to promote innovation in technology
for advanced research and development.
"Emerging infectious diseases can present serious threats to our
nation's health security," said Rick
Bright, Ph.D., Deputy Assistant Secretary for Preparedness
and Response and Director of BARDA at ASPR. "Working as
public-private partners like we have with Regeneron since 2014, we
can move rapidly to respond to new global health threats."
About Regeneron
Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, infectious
diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune® which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Forward-Looking Statements and Use of Digital
Media
This press release includes forward-looking
statements that involve risks and uncertainties relating to future
events and the future performance of Regeneron Pharmaceuticals,
Inc. ("Regeneron" or the "Company"), and actual events or results
may differ materially from these forward-looking statements.
Words such as "anticipate," "expect," "intend," "plan," "believe,"
"seek," "estimate," variations of such words, and similar
expressions are intended to identify such forward-looking
statements, although not all forward-looking statements contain
these identifying words. These statements concern, and these
risks and uncertainties include, among others, the potential for
any license or collaboration agreement, including Regeneron's
agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries
Ltd. (or their respective affiliated companies, as applicable) and
the agreements with the Biomedical Advanced Research and
Development Authority of the U.S. Department of Health and Human
Services discussed in this news release, to be cancelled or
terminated without any product success; the nature, timing, and
possible success and therapeutic applications of products marketed
by Regeneron and/or its collaborators (collectively, "Regeneron's
Products") and Regeneron's product candidates and research and
clinical programs now underway or planned, including without
limitation REGN-EB3 (Regeneron's multi-antibody therapy to Ebola
virus infection); uncertainty of market acceptance and commercial
success of Regeneron's Products and product candidates and the
impact of studies (whether conducted by Regeneron or others and
whether mandated or voluntary) on the commercial
success of Regeneron's Products and product candidates; the
availability and extent of reimbursement of Regeneron's Products
from third-party payers, including private payer healthcare and
insurance programs, health maintenance organizations, pharmacy
benefit management companies, and government programs such as
Medicare and Medicaid; coverage and reimbursement determinations by
such payers and new policies and procedures adopted by such payers;
competing drugs and product candidates that may be superior to
Regeneron's Products and product candidates; unforeseen safety
issues resulting from the administration of Regeneron's Products
and product candidates in patients, including serious complications
or side effects in connection with the use of Regeneron's Products
and product candidates in clinical trials; the likelihood and
timing of possible regulatory approval and commercial launch of
Regeneron's product candidates and new indications for Regeneron's
Products; the extent to which the results from the research and
development programs conducted by Regeneron or its collaborators
may be replicated in other studies and lead to therapeutic
applications; ongoing regulatory obligations and oversight
impacting Regeneron's Products, research and clinical programs, and
business, including those relating to patient privacy;
determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to
continue to develop or commercialize Regeneron's Products and
product candidates; the ability of Regeneron to manufacture and
manage supply chains for multiple products and product candidates;
the ability of Regeneron's collaborators, suppliers, or other third
parties (as applicable) to perform manufacturing, filling,
finishing, packaging, labeling, distribution, and other steps
related to Regeneron's Products and product candidates;
unanticipated expenses; the costs of developing, producing, and
selling products; the ability of Regeneron to meet any of its
financial projections or guidance and changes to the assumptions
underlying those projections or guidance; and risks associated with
intellectual property of other parties and pending or future
litigation relating thereto (including without limitation the
patent litigation and other related proceedings relating to
Dupixent® (dupilumab) and Praluent®
(alirocumab)), other litigation and other proceedings and
government investigations relating to the Company and/or its
operations, the ultimate outcome of any such proceedings and
investigations, and the impact any of the foregoing may have on
Regeneron's business, prospects, operating results, and financial
condition. A more complete description of these and other
material risks can be found in Regeneron's filings with the U.S.
Securities and Exchange Commission. Any forward-looking
statements are made based on management's current beliefs and
judgment, and the reader is cautioned not to rely on any
forward-looking statements made by Regeneron. Regeneron does
not undertake any obligation to update publicly any forward-looking
statement, including without limitation any financial projection or
guidance, whether as a result of new information, future events, or
otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website (http://newsroom.regeneron.com) and its
Twitter feed (http://twitter.com/regeneron).
Regeneron Contacts:
Media Relations
Alexandra Bowie
Tel: +1 (914) 847-3477
Alexandra.bowie@regeneron.com
Investor Relations
Justin Holko
Tel: +1 (914) 847-7786
Justin.holko@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-announces-expanded-collaboration-with-hhs-to-develop-antibody-treatments-for-new-coronavirus-300998140.html
SOURCE Regeneron Pharmaceuticals, Inc.